Using blood fatty acids to predict cognitive decline and dementia early
Developing a blood fatty acid-based algorithm as an early predictor of cognitive decline and dementia: Applying machine learning to harmonized data from prospective cohort studies
This study is looking at whether measuring fatty acids in your blood can help spot early signs of memory problems or Alzheimer's disease, so we can find people at risk before they show serious symptoms, and it’s designed for anyone interested in understanding their brain health better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Omegaquant Analytics, LLC NIH-funded |
| Lab location | 1 site (Sioux Falls, United States) |
| Project ID | NIH-10820645 on NIH RePORTER |
What this research studies
This research investigates the potential of using blood fatty acid levels as an early indicator of cognitive decline and dementia, particularly Alzheimer's disease. By applying machine learning techniques to harmonized data from various cohort studies, the project aims to identify high-risk individuals before significant symptoms appear. Participants may undergo blood tests to measure their fatty acid levels, which could provide insights into their cognitive health and allow for timely interventions. The goal is to develop a cost-effective and accessible predictive algorithm that can help in early diagnosis and management of dementia.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults aged 65 and above who may be at risk for Alzheimer's disease or related dementias.
Not a fit: Patients who are already diagnosed with advanced dementia or cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable earlier detection of cognitive decline, allowing for timely interventions that may slow or prevent the progression of dementia.
How similar studies have performed: Previous research has shown promise in using biomarkers for early detection of Alzheimer's disease, suggesting that this approach could be a valuable addition to existing methods.
Where this research is happening
Sioux Falls, United States
- Omegaquant Analytics, LLC — Sioux Falls, United States (Active)
Researchers
- Principal investigator: Harris, Bill — Omegaquant Analytics, LLC
- Study coordinator: Harris, Bill
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.